Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
is that the real Meowza. aka Dmiller, Sybil, Steve. Come on man. I put you on ignore but you keep changing your ID.
BB of course.
yes, I tried but no return calls. I've researched the qtrly slide decks updates from Amarin and the footnote in the financial section has a reduction of the preferred series A from 29 mill down to 5 mill. I guess we'll find out next wk when they file 13d if they still hold their original 34 mill shares. (29mill plus 5mill) 5 mill is owned by 669 LLC fund which is one of their holding companies. Honestly, I doubt it. They purchased the series A for under $1.00 If I recall it was somewhere around .50cents.
No. They're not the sharpest knifes in the draw. I callled 3 times today. I'll keep trying if i don't get answer I'll go beyond customer service to upper management.
BB, I'm waiting for a call back from a Hikma customer service rep. I asked when would GV be available. Her computer was slow to start so she couldn't search for the info. She's supposed to call me back with info. LOL FYI, They have relocated their Eatontown office to Berkeley Heights, NJ not far from Amarin.
jasbg, watch newsmax drop fox, twitter and fb go to parler.com. More upbeat positive reporting.
BB
Does sorbitol cause cancer?
Plum juice and prunes — a perennial, popular laxogenic food — contain sorbitol, a sugar alcohol that is behind blindness and nerve damage, including anorectal — a primary cause of age-onset irregularity and constipation which in turn may cause colorectal cancer.
Colon cancer prevention: Avoid common cancer triggers
www.gutsense.org/colon-cancer/avoid-cancer-triggers.html
www.gutsense.org/colon-cancer/avoid-cancer-triggers.html
BB, is this sorbitan a derivative of sorbitol that is being banned in many products as it can be cancerous? Holy cow.
sts, thanks I found it. Hikma has deleted all other references. I'm going to call the local office tomorrow to ask when they expect to start retailing the generic brand. I'll post after I speak to the sales rep.
Yes indeed. I wanted to respond but no means of doing so.
rosemount, thanks, got it.
BB, shorts aren't interested in a 4 dollar number. I doubt that Baker Bros. would short common shs of amrn. It has to be in their charter. Maybe they wrote covered calls?
By chance did you or anyone catch Cramer's response during his 6 o'clock show? Someone called in from Illinois ask about his thoughts about Amarin he shook his head and said something like they got turned down by FDA for their drug??? Very disappointed in his response. Dopey.
BB, sorry still 0 results if I search vas, generic vascepa.
BB, the link you listed brings up the search bar, search vascepa and it comes up 0. Where is the quote you posted? Thanks
bio, I was the person who noticed that Amarin slide deck footnotes in the financial section noted that the amount of the convertible preferred has been reduced to approx 5 million whereas the previous months had it listed close to 26million. reference page 22. I believe that number references the BB holdings.
https://investor.amarincorp.com/static-files/d6b5bb48-f4f6-4d84-b565-37abd27d3f6a
sts, BB pointed that out several weeks ago. After GSK won the infringement appeal against Teva, Hikma removed all reference to future GV sales estimated to be $752million that clearly indicated they intended to infringe. All references to GV were deleted.
P-file, It's an extremely frustrating scenario we find ourselves in, I have owned my own business it's a balancing act btw personalities and getting the job done. We're dealing with someone who has tunnel vision (JT) and a BOD that doesn't give a hoot. If they did care they would have fired JT's sorry ass.
jasbg/HK, a very sad situation for all shareholders. Great product but very bad management. Let's get rid of the bums! Dead money until something positive happens like JT steps down. I fear the worst is yet to come if Amarin GIA in EU and ROW! Big mistake. ((
johnhan, are you aka Jeffrey Toobin??
jasbg/sts, it's a very real story. Belford was a really bad guy, I'm speaking from my past experience dealing with the low lives of wall street. It's all true Belford helped write the movie when he was in jail!!! LOL
cbb, Thanks for your insightful thoughts. You are probably correct re your assumption about BB wanting JT to hit the bid when BP made a reasonable offer. Maybe that's why they sold out. We'll know for sure when they file they 13D in mid Nov.
level, does it matter that the first amicus mentions Amarin and in second filing it's deleted??
gary, does this mean that the vascepa label for high trigs will be pulled from the mkt thus invalidating it's use thereby preventing Hikma to launch GV.
Raf, why doesn't this update from Piper show up as a newsfeed next to the share price? How can we get it as a news item? Let me think on this one.
#sleven, I won't be around that long. I need to move on.
#sleven how many yrs does that take?
I have no idea what the procedure would be to change the label. Maybe BB will know???
Yes, don't shot the messenger. I'm just posting as the news is released from news feeds.
BRIEF-Vascepa (Icosapent Ethyl) Found To Significantly Reduce Ischemic Events In Patients With Prior Percutaneous Coronary Intervention In Post HOC Subgroup Analyses Of Landmark Reduce-It Study
REUTERS 5:14 PM ET 10/15/2020
Symbol Last Price Change
AMRN 5.05down +0.1 (+2.0202%)
QUOTES AS OF 04:00:00 PM ET 10/15/2020
Oct 15 (Reuters) - Amarin Corporation PLC(AMRN):
* VASCEPA® (ICOSAPENT ETHYL) FOUND TO SIGNIFICANTLY REDUCE ISCHEMIC EVENTS IN PATIENTS WITH PRIOR PERCUTANEOUS CORONARY INTERVENTION (PCI) IN POST HOC SUBGROUP ANALYSES OF LANDMARK REDUCE-IT® STUDY PRESENTED AT TRANSCATHETER CARDIOVASCULAR THERAPEUTICS (TCT) CONNECT 2020 Source text for Eikon: Further company coverage:
New Analyses Show Amarin's Vascepa Reduces Ischemic Events in Angioplasty Patients -- Stock Up 5% After-Hours
MT NEWSWIRES 4:55 PM ET 10/15/2020
Symbol Last Price Change
AMRN 5.05down +0.1 (+2.0202%)
QUOTES AS OF 04:00:00 PM ET 10/15/2020
04:55 PM EDT, 10/15/2020 (MT Newswires) -- Amarin(AMRN) said on Thursday new analyses showed that its Vascepa drug reduced ischemic events in patients who had prior percutaneous coronary intervention (PCI), meaning that patients who have undergone angioplasty with stents to open up their blood vessels.
"The findings of benefit in at-risk patients with prior PCI are consistent with previously presented data on overall reductions in first and total coronary revascularization events of 34% and 36%, respectively," said principal investigator Deepak Bhatt.
"The statistically significant substantial benefit in reduced coronary revascularization procedures seen as early as 11 months provides clinicians with a potential additional intervention in a patient population for whom time is of the essence."
Price: 5.28, Change: +0.23, Percent Change: +4.55
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
©http://www.mtnewswires.com Copyright © 2020 MT Newswires. All rights reserved.
If you're talking about Judge Barrett, see gets my vote. That's worth at least -.01cent.
Good thought!
It's a robust annoucement!! LOLOLOL
VASCEPA ® , c ompared with placebo, significantly reduced primary composite first and total MACE (m ajor a dverse c ardiovascular e vents ) in post hoc exploratory analyses of patients with a history of PCI by 34% and 39% , respectivel y, and k ey secondary composite first hard MACE , comprised of heart attacks, stroke and cardiovascular death, by 34%
Administration of VASCEPA resulted in r obust absolute risk reductions of 8.5% and 5.4% and number s needed to treat (NNT) of 12 and 19, respectively , for both primary and key secondary (hard MACE) composite endpoints in post hoc exploratory subgroup analyses
Consistent and robust benefit seen in post hoc exploratory analyses of patients with a history of PCI across the hierarchy of endpoints prespecified for the full study cohort
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc(AMRN) today announced the presentation of REDUCE-IT® PCI at Transcatheter Cardiovascular Therapeutics (TCT) Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation, being held virtually from October 14 – October 18, 2020 adding to the growing body of knowledge on the clinical impact of VASCEPA® (icosapent ethyl). These new analyses supported by Amarin(AMRN) were presented during the TCT Connect 2020 Best of Abstracts session by Benjamin E. Peterson, M.D., Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School.
“The opportunity to further explore REDUCE-IT data and effects in those patients with prior PCI provides additional understanding of the potential benefit of icosapent ethyl in the clinical setting,” commented Dr. Deepak L. Bhatt, M.D., M.P.H., Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School, principal investigator of REDUCE-IT and senior author of the REDUCE-IT PCI analyses. “The findings of benefit in at-risk patients with prior PCI are consistent with previously presented data on overall reductions in first and total coronary revascularization events of 34% and 36%, respectively. Moreover, the statistically significant substantial benefit in reduced coronary revascularization procedures seen as early as 11 months provides clinicians with a potential additional intervention in a patient population for whom time is of the essence.”
The REDUCE-IT PCI analysis looked at 3,408 (41.7%) of patients enrolled in REDUCE-IT who had undergone a prior PCI. These patients were randomized a median of 2.9 years after PCI. Baseline characteristics were similar among patients randomized to VASCEPA versus placebo. Post hoc exploratory analyses of the subgroup of 3,408 patients with a prior PCI showed that, for the primary composite endpoint of 5-point MACE, time to first event was significantly reduced with VASCEPA versus placebo by 34% (p<0.0001) and total (first and subsequent) events were also reduced by 39% (p<0.0001). For the key secondary composite endpoint of 3-point MACE, time to first event was reduced by 34% (p<0.0001) in the subgroup of patients with a prior PCI.
Coronary revascularization procedures, such as stenting, are invasive, carry multiple risks, and can have significant direct and indirect costs. Patients with elevated triglycerides despite statin therapy have increased risk for ischemic events, including coronary revascularizations. These procedures, whether pre-scheduled or performed in an emergency, inevitably result in additional time spent in a healthcare setting. The latest statistical update from the American Heart Association (AHA) shows that, in 2014, an estimated 480,000 inpatient PCI procedures were performed in the United States with a mean inpatient hospital charge for PCI of $84,813.1
“Revascularization procedures overall significantly impact the healthcare system, with PCI procedures adding to the burden and driving substantial costs,” said Steven Ketchum, Ph.D., senior vice president and president, research & development and chief scientific officer, Amarin(AMRN). “The subgroup data presented at TCT Connect 2020 reflect new findings demonstrating the substantial impact of VASCEPA on at-risk patients in REDUCE-IT with prior PCI procedures and how the therapy can help avoid subsequent events that could have dire consequences.”
REDUCE-IT was not specifically powered to examine individual cardiovascular endpoints or patient subgroups, therefore p-values presented for these revascularization analyses are nominal and exploratory with no adjustment for multiple comparisons. In addition, coronary revascularization as an endpoint can sometimes be considered subjective; however, these endpoints were adjudicated by an independent, blinded clinical endpoint committee. Results from the total coronary revascularization events analyses are consistent across the various recurrent event statistical models and are also consistent with the first coronary revascularization events results. Together, the REDUCE-IT first and total coronary revascularization events results support the robustness and consistency of the clinical benefit of VASCEPA therapy in reducing coronary revascularization.
news on amarin I'll post link.
In spite of the total ineptness of the entire management team of Amarin, I'm going out on a limb and state that I believe AMRN share price has bottomed. The scenario has totally changed since the GSK vs Teva ruling. There's hope for us bagholders!!!! lol
ralph, Thanks but this is old news, the next filing will be Nov. 15.
Marjac, I believe the amicus brief found its way to Hikma's management, compounded by the GSK VS Teva results may have caused their legal ppl to advise them to remove all reference to their patent win along with any mention of GV projection because it proved their intent to infringe and I think it implies that they are guilty of fraud too. Hikma would be tied up in court for yrs. It's not worth their time and money.
I put him on ognore but his posts still showed up. I'll pm you with his bs.
Dmiller has posted some nasty stuff. Search his alias. I think he's actually mrc, steve giardino.